U.S. Ketamine Clinics Market Size, Share, & Trends Analysis Report By Treatment (Depression, Anxiety, PTSD, Others), By Therapy (On-site Therapy, Online Therapy),- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

U.S. Ketamine Clinics Market Size and Trends

The U.S. ketamine clinics market size was exhibited at USD 3.95 billion in 2023 and is projected to hit around USD 10.84 billion by 2033, growing at a CAGR of 10.62% during the forecast period 2024 to 2033.

U.S. Ketamine Clinics Market Key Takeaways:

• The depression segment dominated the market in 2023 with a market share of 30.15%.
• The anxiety segment is anticipated to grow fastest during the forecast period.
• The onsite therapy segment dominated the market in 2023 with a revenue share of 53.0%.
• The online therapy segment is expected to grow at the fastest growth rate during the forecast period.

Report Scope of U.S. Ketamine Clinics Market

The U.S. market is expected to grow significantly, driven by an increase in use of ketamine for various therapies, along with the expanding number of clinics offering ketamine treatments for mental health disorders. Increasing investment and partnerships are significantly driving the growth of ketamine clinics. This trend is majorly driven by the rising recognition of ketamine's potential in treating various mental health disorders, such as depression and Post-Traumatic Stress Disorder (PTSD), which has attracted substantial interest from investors as well as healthcare providers.

According to Mental Health America, the prevalence of adult mental illness in the U.S. ranges from 16.37% to 26.86%. On average, 19.86% of adults experience mental illness, which is equivalent to over 50 million Americans; among that, 4.91% are experiencing a severe mental illness.

The opioid crisis in the U.S. has contributed to the growth of the ketamine clinics market, as ketamine offers a nonopioid alternative for managing chronic pain. Ketamine can provide rapid relief of depressive symptoms, often within hours, compared to weeks for traditional antidepressants. This quick turnaround is crucial for patients with severe depression or suicidal ideation.

In a study conducted by the University of Michigan in February 2024, known as the Bio-K study, ketamine infusions were administered to 74 patients at four clinics in Minnesota, Maryland, and Michigan. The study reported that 52% of participants experienced significant relief from depression after receiving three ketamine infusions over the course of 11 days. Moreover, 50% of participants reported a significant decline in suicidal tendencies.

The increasing amount of research on ketamine's therapeutic potential has contributed to the market growth. For instance, in January 2022, the U.S. FDA approved a Phase 2 clinical trial for PharmaTher's experimental treatment for Amyotrophic Lateral Sclerosis (ALS), which involves the psychedelic ketamine. This trial aimed to enroll three groups of patients. The study used a multiple ascending dose design to determine if any doses of intravenous ketamine cause toxicity after 12 or 24 weeks (three or six months). Consequently, an increasing number of clinics are offering ketamine treatments, and ongoing research is exploring its potential benefits and long-term effects.

U.S. Ketamine Clinics Market By Treatment Insights

The depression segment dominated the market in 2023 with a market share of 30.15%. The growth of the segment can be attributed to the increase in the prevalence of major depressive disorder.During 2020-2021, the percentage of adults with depression and anxiety increased from 36.4% to 41.5%, according to the CDC. Moreover, the growing number of American adults burdened with severe major depression is expected to fuel the segment growth. According to the National Institute of Mental Health, in 2021, it was estimated that 14.5 million U.S. adults aged 18 and above suffered from at least one major depression episode, which represented 5.7% of all American adults.

The anxiety segment is anticipated to grow fastest during the forecast period. Anxiety disorders are the most widespread mental illness in the U.S. As per data provided by the Anxiety and Depression Association of America, approximately 6.8 million adults and more than 31.9% of adolescents aged 13 to 18 years were affected by anxiety disorders in 2021. Moreover, the COVID-19 pandemic has increased anxiety and stress levels, leading to an amplified need for treatment and support for anxiety disorders, thereby driving the segment growth.

U.S. Ketamine Clinics Market By Therapy Insights

The onsite therapy segment dominated the market in 2023 with a revenue share of 53.0%. Onsite therapy provides a controlled and supervised setting, ensuring the safety of patients and maximizing treatment results. During the therapy sessions, patients receive individualized care, monitoring, and support, which can improve the overall treatment experience and increase patient satisfaction..

This growing popularity has resulted in a significant rise in the number of ketamine clinics throughout the U.S. There are currently hundreds of these facilities across the country, and this number continues to grow yearly. This expansion reflects the growing acceptance of ketamine as a valuable form of mental health treatment, thereby driving the segment's growth.

The online therapy segment is expected to grow at the fastest growth rate during the forecast period. The growth of this segment is attributed to the rise of telehealth and remote healthcare services, the accessibility and convenience of online ketamine therapy have expanded significantly. The COVID-19 pandemic has further accelerated this trend, as virtual healthcare options gained prominence due to social distancing measures. As a result, the demand for online therapy has increased, contributing to the segment growth.

U.S. Ketamine Clinics Market Recent Developments

• In February 2024, Innerwell (KBS, Inc.) expanded into in-network care by partnering with four major insurance providers in California and two in New York. This expansion is expected to broaden consumer access to Innerwell’s innovative treatments, which include traditional psychiatry, talk therapy, ketamine treatment, and EMDR.
  
  
• In December 2023, Mindbloom, Inc. launched its Mastermind Series, the first expert-led psychedelic therapy program designed to address heartbreak, burnout, and other mental health issues. Developed in collaboration with leading experts, these programs integrate specialized teachings with ketamine therapy to boost neuroplasticity and promote lasting change.
• In January 2023, Nue Life Health launched the Nue Network, a partnership program designed to expand access to its HIPAA-compliant, at-home ketamine treatment & integration therapy programs.
  
  
• In March 2022, Field Trip Health partnered with Cerebral, facilitating a mutual referral system. Cerebral clinicians could refer eligible clients to Field Trip Health for ketamine-assisted therapy, while Field Trip could refer individuals seeking general psychiatry & teletherapy services to Cerebral. This collaboration aimed to offer personalized treatment options for individuals seeking to enhance their mental well-being.

Some of the prominent players in the U.S. ketamine clinics market include:

• Better U, Inc.
• Innerwell (KBS, Inc.)
• Ketamine Clinics Los Angeles
• Klarisana Health
• Klarity Clinic (Tebra Inc.)
• Mindbloom, Inc.
• Nue Life Health (NueCo Holdings, P.B.C.)
• NY Ketamine Infusions
• Stella MSO LLC dba Field Trip Health
• Vitalitas Denver Ketamine Infusion Center

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. ketamine clinics market

Treatment

• Depression
• Anxiety
• PTSD
• Others

Therapy

• On-Site Therapy
• Online Therapy